Giovanni Coppi

Dr. Giovanni Coppi

orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2014 in European Journal of Vascular and Endovascular Surgery
Verified
Journal Article
Closed access
GCGiovanni Coppi
Giovanni Coppi
GSG. Saitta
G. Saitta
SGS. Gennai
S. Gennai
ALA. Lauricella
A. Lauricella
RSR. Silingardi
R. Silingardi

9 July 2016 in Journal of Endovascular Therapy
Verified
Journal Article
Closed access
RSRoberto Silingardi
Roberto Silingardi
GCGiovanni Coppi
Giovanni Coppi
EFEmanuele Ferrero
Emanuele Ferrero
ALAntonio Lauricella
Antonio Lauricella
DPDaniele Psacharopulo
Daniele Psacharopulo
MFMichelangelo Ferri
Michelangelo Ferri
Purpose: To report midterm outcomes of the Nellix Endovascular Aneurysm Sealing (EVAS) System in the treatment of abdominal aortic aneurysm (AAA). Methods: Between September 2013 and July 2014, 64 AAA patients (mean age 76.6±6.8 years; 61 men) were treated with the EVAS system at 2 centers (only procedures performed at least 12 months prior to the analysis were included). Most patients were treated for a stable AAA, while 1 patient was treated for a ruptured aneurysm. Mean aneurysm diameter was 57.3±9.3 mm. The proximal neck measured a mean 21.5±3.3 mm in diameter and 27.0±12.1 mm long; the neck angle was 16.9°±19.3°. Eleven (17.2%) patients were treated outside the instructions for use (IFU). Results: Technical success was achieved in 63 (98.4%) of 64 patients; 1 type Ia endoleak was treated intraoperatively. One (1.6%) aneurysm-related death occurred at 4 months due to a secondary aortoenteric fistula. Overall, endoleaks occurred in 3 (4.7%) patients (2 type Ia, 1 type II). The estimated rates for 18-month overall survival, freedom from aneurysm-related death, and freedom from secondary interventions were 92.7%, 98.4%, and 95.0%, respectively. Patients treated outside the IFU had a significantly higher incidence of device-related complications (p=0.03). Conclusion: The use of the Nellix device in everyday clinical practice is safe and offers promising midterm results. The risk of secondary aortoenteric fistula requires further analysis. Longer follow-up is needed to assess the actual efficacy of the device, although the risk of migration with late endoleak seems low.

1 March 2015 in Journal of Vascular and Interventional Radiology
Verified
Journal Article
Closed access
RSRoberto Silingardi
Roberto Silingardi
ALAntonio Lauricella
Antonio Lauricella
GCGiovanni Coppi
Giovanni Coppi
ENEmanuele Nicolosi
Emanuele Nicolosi
SGStefano Gennai
Stefano Gennai
GCGioacchino Coppi
Gioacchino Coppi

1 April 2015 in Journal of Vascular and Interventional Radiology
Verified
Journal Article
Closed access
GCGiovanni Coppi
Giovanni Coppi
GSGiuseppe Saitta
Giuseppe Saitta
ALAntonio Lauricella
Antonio Lauricella
RSRoberto Silingardi
Roberto Silingardi

1 August 2012 in Annals of Vascular Surgery
Verified
Journal Article
Closed access
PDF file
GCGiovanni Coppi
Giovanni Coppi
Yamume TshombaYamume Tshomba
Yamume Tshomba
DPDaniele Psacharopulo
Daniele Psacharopulo
Enrico Maria MaroneEnrico Maria Marone
Enrico Maria Marone
RCRoberto Chiesa
Roberto Chiesa

1 May 2019 in Annals of Vascular Surgery
Verified
Journal Article
Closed access
RSRoberto Silingardi
Roberto Silingardi
GCGiovanni Coppi
Giovanni Coppi
FBFrancesca Benassi
Francesca Benassi
GSGiuseppe Saitta
Giuseppe Saitta
LMLuigi Marcheselli
Luigi Marcheselli
SGStefano Gennai
Stefano Gennai